Vireo Growth (VREOF) Cash from Investing Activities (2020 - 2026)
Vireo Growth (VREOF) reported Cash from Investing Activities of $8.0 million for Q1 2026, up 827.27% on a YoY basis from $862745.1 in Q1 2025, and up 184.91% sequentially from -$9.4 million in Q4 2025.
Vireo Growth (VREOF) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Cash from Investing Activities data on file, last reported at $8.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 827.27% year-over-year to $8.0 million; the trailing twelve-month figure through Mar 2026 stood at $17.9 million (up 318.25% YoY), and the FY2025 full-year result was $8.8 million, up 207.71% from the prior year.
- Cash from Investing Activities improved to $8.0 million in Q1 2026, from -$9.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $34.0 million in Q2 2025 to a low of -$14.8 million in Q3 2025.
- A 5-year average of -$27337.1 and a median of -$1.1 million in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities sank 1423.26% in 2024 and soared 1167.2% in 2025, its largest moves.
- Tracing VREOF's Cash from Investing Activities over 5 years: stood at -$819539.0 in 2022, then jumped by 79.11% to -$171183.0 in 2023, then slumped by 1423.26% to -$2.6 million in 2024, then tumbled by 261.33% to -$9.4 million in 2025, then soared by 184.91% to $8.0 million in 2026.
- Business Quant data shows VREOF's Cash from Investing Activities at $8.0 million in Q1 2026, -$9.4 million in Q4 2025, and -$14.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 90.13 Bn | 88.27 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 8.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.00 Mn |
| Mar 31, 2026 | 8.00 Mn |
| Dec 31, 2025 | -9.42 Mn |
| Dec 31, 2025 | -9.42 Mn |
| Sep 30, 2025 | -14.76 Mn |
| Sep 30, 2025 | -14.76 Mn |
| Jun 30, 2025 | 34.04 Mn |
| Jun 30, 2025 | 34.04 Mn |
| Mar 31, 2025 | -1.10 Mn |
| Mar 31, 2025 | -1.10 Mn |
| Dec 31, 2024 | -2.61 Mn |
| Dec 31, 2024 | -2.61 Mn |
| Sep 30, 2024 | -1.29 Mn |
| Sep 30, 2024 | -1.29 Mn |
| Jun 30, 2024 | -3.19 Mn |
| Jun 30, 2024 | -3.19 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | -171,183.00 |
| Dec 31, 2023 | -171,183.00 |